Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyxeos in Higher-risk MDS after HMA Failure
NCT04109690Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Dec 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine in myelodysplastic syndrome (MDS), sponsored by Yale University. Planned start Dec 2019; status: withdrawn.
02
Drugs
cytarabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04109690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109690.